You searched for cnsp - Page 6 of 21

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Faith L. Charles as chair of its board of directors. Since 2010, Charles has served as a corporate transactions and securities partner at the … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD”

A Phase 2, globally sited clinical trial evaluating the potential efficacy of a promising brain cancer drug candidate against deadly glioblastoma (“GBM”) tumors is proceeding apace with a variety of patient profiles, affirming the drug developer’s confidence in its product. In a Dec. 8 news release, CNS Pharmaceuticals (NASDAQ: CNSP) reported that 67 patients have … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial”

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event held December 6. As part of the virtual event, Climaco discussed his and the company’s background, provided an update on recent key events and plans for the 2023 calendar year, and assuaged investors’ concerns regarding the recent reverse … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations”

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward”

On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment”

The most common primary brain cancer in adults and one of the most aggressive, glioblastoma, remains a critical unmet medical need because of its level of morbidity and the lack of effective treatment options nearly a century after it was defined by pioneering neurosurgeons Percival Bailey and Harvey Cushing in 1926. Glioblastoma, known simply as … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor “Ask the CEO” event. The live, moderated event is intended to provide the investment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place”